Morgan Stanley lowered the firm’s price target on Bath & Body Works to $50 from $61 and keeps an Overweight rating on the shares. The firm, which is updating estimates post-Q3, keeps its mid-term operating assumptions largely unchanged, but its price target falls on a lower FY24 base year and updated cost of capital assumptions. The firm’s FY24 EPS forecast is down by over 15% on management’s cautious 2024 growth commentary, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BBWI:
- Bath & Body Works reaffirms Q4, FY23 net sales guidance
- Bath & Body Works to Present at the Morgan Stanley Global Consumer & Retail Conference
- Bath & Body Works price target lowered to $35 from $52 at TD Cowen
- Bath & Body Works price target lowered to $42 from $52 at Telsey Advisory
- Bath & Body Works price target lowered to $30 from $40 at Evercore ISI